+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

IVD Market Brief Update

  • ID: 5521658
  • Report
  • November 2021
  • Region: Global
  • 39 Pages
  • Kalorama Information

What is the Size of the IVD Market in 2021?

 

What Major Trends are Affecting the Market in 2021?

Diagnostic test products have never been more important. This report is an update of the market for in vitro diagnostics products from Kalorama’s analysts to reflect the latest information as of Q4 2021. As part of its coverage, this report contains market sizing for several major categories of IVD.


The demand for testing and movement of current and new technologies has continued to demonstrate gains in most areas of the IVD market. New products, changes in global health spending, regulatory changes in major markets, and disease trends are among the factors that produce a constantly evolving market picture. There are some growing segments in the market that have attracted industry attention. Among these are next-generation sequencing (NGS), cancer testing, and companion diagnostics technologies. Immunochemistry, point- of-care (POC) testing, and molecular diagnostics are also segments of great market interest, anticipated to be a big part of the future of IVD. The IVD market remains dynamic, demonstrating constant innovations.


Kalorama Information has been diligent in outlining the IVD market and its rapidly changing landscape. COVID-19 has provided many positive aspects for the IVD diagnostic market but forecasting the market has become very difficult due to the uncertain progression of COVID-19. Kalorama Information has been superior in accessing the market due to the extensive experience of its authors and commitment by the company to present the most accurate data available.


Note: Product cover images may vary from those shown

CHAPTER 1: WORLDWIDE IVD MARKET - Q4 2021 UPDATE 

IVD MARKET DEMAND AND GROWTH 
Table 1-1: Global In Vitro Diagnostic Sales by Product Market, 2021 ($ million) (Clinical Chemistry; Immunoassays - non isotopic: Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c - lab; Hematology - Core Lab; Microbiology (ID/AST); Microbiology (molecular); Microbiology - Mass Spectrometry; Coagulation (PT/INR); Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular - NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC,
professional/hospital; Mass Spectrometry; Other IVD) 
COVID-19 DIAGNOSTIC MARKETS 
Table 1-2: COVID-19 Product Sales - Immunoassay (Antigen, Serology), Molecular, POC -, 2021 ($millions)
EFFECT OF COVID-19 ON MARKET SEGMENTS 
Table 1-3: IVD Market excluding and with COVID-19, 2021 
Figure 1-1: IVD Market Distribution by Segment 
Table 1-4: Global In Vitro Diagnostic Market - YoY Growth 2020-2021 
Figure 1-2: Global In Vitro Diagnostic Market - YoY Growth 2020-2021 
Figure 1-3: IVD Segment Performance, Q1 2021 - Q4 2021 
Figure 1-4: IVD Segment Performance, Total Market Value, 2021 


CHAPTER TWO: PRODUCT TRENDS AND NEW DEVELOPMENTS 

SELECTED NEW CORE IVD PRODUCT LAUNCHES AND DEVELOPMENTS 
Clinical Chemistry 
Hematology 
Molecular 
Companion Diagnostics 
Microbiology 
POC
Mass Spectrometry 
COVID-19 Developments - September 2021 and Beyond 
Figure 2-1: COVID-19 Test Market by Type, Q1-Q4 2021 Estimates - Rapid Testing Markets Remain
Strong 
Antigen 
Serology 
Molecular 


CHAPTER THREE: SELECTED IVD MARKET PARTICIPANT DEVELOPMENTS 

SELECTED COMPETITIVE LEADER UPDATES 
Figure 3-1: IVD Segment Growth by Leading Competitors, Change in Sales 2020-2021
Figure 3-2: Changes in Market Distribution for IVD Sales, 2019 & 2021 - Roche and Abbott Tie for #1
Spot 
Q3 M&A ACTIVITY 
Table 3-1: IVD Market M&A Activity, Q3 2021 
ABBOTT LABORATORIES 
Table 3-2: Abbott Corporate Summary 
Company Update 
AGILENT 
Table 3-3: Agilent Summary 
Company Update 
BECTON DICKINSON AND CO 
Table 3-4: BD Corporate Summary 
Company Update 
BIOMÉRIEUX SA 
Table 3-5: bioMérieux Corporate Summary
Company Update 
DANAHER 
Table 3-6: Danaher Corporation Summary 
Company Update 
HOLOGIC, INC. 
Table 3-7: Hologic Corporate Summary 
Company Update 
ILLUMINA 
Table 3-8: Illumina Corporate Summary 
Company Update 
ORTHO CLINICAL DIAGNOSTICS 
Table 3-9: Ortho Clinical Corporate Summary 
Company Update 
PERKIN ELMER 
Table 3-10: Perkin Elmer Corporate Summary 
Company Update 
QUIDEL CORPORATION 
Table 3-11: Quidel Corporate Summary 
Company Update 
ROCHE DIAGNOSTIC 
Table 3-12: Roche Diagnostic Corporate Summary 
Company Update 
SIEMENS HEALTHINEERS 
Table 3-13: Siemens Healthineers Corporate Summary 
Company Update 
THERMO FISHER SCIENTIFIC 
Table 3-14: Thermo Fisher Scientific Corporate Summary 
Company Update 


CHAPTER FOUR: NEW OPPORTUNITIES 

TELEHEALTH AND REMOTE PATIENT MONITORING UPDATE 
Figure 4-1: Teladoc Quarterly Telehealth Services Performance 2020 and H1 2021 ($M) 
MULTIPLEX AND SYNDROMIC TESTING 
PERSONALIZED MEDICINE 
POINT-OF-CARE 


 


Note: Product cover images may vary from those shown